Phase 2 Study of Oral K201 for Prevention of AF Recurrence
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, efficacy, and tolerability of 3 doses of K201 (oral) administered for
up to 28 days in subjects with recent DC cardioversion to sinus rhythm from sustained
symptomatic atrial fibrillation (AF duration >3 days and <6 months).